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Melanoma, the most lethal form of skin cancer, has increased in 
incidence and mortality over the last 3 decades. Metastatic disease 
that is not amenable to surgery is generally refractory to therapy 
and, therefore, ultimately lethal. Standard chemotherapy typically 
produces response rates on the order of 10%, and radiotherapy 
plays only a limited role in disease palliation. Despite these sober-
ing facts, some optimism has been engendered by recent advances 
in our molecular understanding of the disease, particularly the 
finding that approximately 80% of metastatic melanomas (MMs) 
harbor mutually exclusive activating mutations of either N-RAS 
or B-RAF (reviewed in ref. 1). These lesions lead to activation of 
the RAF/MEK/ERK/MAPK pathway, which in turn controls the 
transcription of hundreds if not thousands of genes related to cel-
lular proliferation, survival, and motility (2). Although work in 
murine models and pharmacological approaches have suggested 
that RAS-RAF activation is required not only for tumor formation, 
but also for tumor maintenance (3, 4), the cell-biological effects of 
ERK activation that are most relevant for tumor formation and 
progression have not been fully established.
Arguably, the evidence for a clinically valuable anticancer 
immune response is stronger in MM than any other human malig-
nancy (reviewed in refs. 5–8). Functional T cells restricted to mela-
noma antigens can be readily recovered from patients with MM, 
establishing the tumor’s immunogenicity in humans (5–7, 9). 
Anecdotal spontaneous remissions, thought to be immune medi-
ated, have been described by multiple investigators, and the 
appearance of vitiligo, an autoimmune response to melanocytes, 
is of good prognostic significance in patients with MM (10–12). 
Therapeutic strategies to augment the immune response, e.g., 
treatment with interferon and IL-2, demonstrate efficacy in certain 
clinical settings (5, 6, 8, 13), and anti-CTLA4 antibodies, which 
enhance T cell activation, have been reported to possess promising 
single-agent activity in early clinical trials (14, 15). Despite these 
findings, however, the majority of patients with MM eventually fail 
immunotherapeutic approaches and succumb to progressive dis-
ease. In particular, antigen-presenting cells, especially DCs, appear 
unable to sufficiently augment the antimelanoma response for 
effective tumor clearance. Melanoma cell lines have been reported 
to repress DC function through the elaboration of soluble factors 
and by direct physical interaction (16–19). These observations 
have in turn motivated clinical strategies to augment DC function 
in melanoma in order to enhance antitumor immunity (20, 21).
Given this background, we considered our recent finding that 
CD200 mRNA correlates with ERK activation in melanoma par-
ticularly provocative (2). CD200, initially described as the Ox-2 
tumor antigen, is a type I membrane-associated glycoprotein and 
a member of the immunoglobulin superfamily (22). It is expressed 
on a variety of cell types, including myeloid cells, endothelium, 
ovarian cells, placental trophoblasts, and neurons. Recent work 
has shown that CD200 induces an inhibitory signal by interact-
ing with CD200 receptors (CD200Rs) expressed on myeloid cells, 
particularly macrophages and DCs (23–25). This interaction gen-
erates signals that negatively regulate immune and inflamma-
tory responses and prevent an autoimmune response in a num-
ber of systems (25–29). Moreover, a few phylogenetically distinct 
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viruses including poxviruses and KSHV, the causative agent of 
Kaposi sarcoma and other human cancers, have been shown to 
attenuate the host antiviral immune response by expressing a 
viral CD200 homolog (30–33). Given the storied history of host-
gene homologs in the ability of DNA tumor viruses to promote 
cancer (e.g., refs. 34–36), we considered this latter finding com-
pelling. Therefore, although 81 other ERK targets, including sev-
eral of likely pathogenic significance (e.g., IL-8, TWIST1, FGF2, 
CXCL1/GRO1), were identified in our genomic screen, these 
facts motivated more detailed study of CD200 in particular. In 
this work, we show that CD200 mRNA and protein are regulated 
by ERK activation, and CD200 is expressed in the majority of 
melanoma but only rarely in other solid tumors. Moreover, this 
expression is immunologically significant, as endogenous levels 
of CD200 on melanoma cell lines attenuate the ability of DCs to 
activate T cells in a mixed lymphocyte reaction (MLR). As block-
ing antibodies to CD200 are in preclinical development, these 
observations suggest that the CD200-CD200R interaction is a 
therapeutic target in melanoma.
Results
CD200 is regulated by the N-RAS/B-RAF/MEK/ERK/MAPK pathway.  
Through the manipulation of ERK signaling in melanoma cell lines, 
we recently demonstrated in 2 independent microarray screens 
that CD200 mRNA expression in melanoma is regulated by the 
N-RAS/B-RAF/MEK/ERK pathway (2). The pattern of CD200 
mRNA expression in melanoma cell lines was similar to that of 
other known ERK targets such as IL-8 and SPRY2: low in normal 
melanocytes and melanoma cells lines with low p-ERK; high in 
cell lines with high expression of p-ERK; and inhibited by U0126, 
a potent MEK inhibitor (Figure 1A). By TaqMan RT-PCR, we 
showed a significant reduction in CD200 mRNA in 2 melanoma 
Figure 1
CD200 is a p-ERK target in melanoma. (A) Dendrogram of melanoma-specific transcripts that are regulated by p-ERK expression in indicated 
melanoma cell lines. Melanoma cell lines with high levels of activated ERK (black) show increased CD200 expression. Melanoma cell lines 
with low ERK activity lacking RAS/RAF mutation (blue) or treated with UO126 (a MEK inhibitor; green) and normal human melanocytes (red) 
have low expression of CD200 and other known ERK targets. (B) TaqMan qRT-PCR of CD200 expression after U0126 treatment of human 
melanoma cell lines. WM2664 and SKMEL24 cell lines were treated with U0126 for 4, 8, and 24 hours. CD200 expression was normalized to a 
control transcript (18S). Error bars are ± SEM. *P < 0.05. (C) Immunoblot showing ERK activation in melanoma cell lines. Protein lysates from 
the indicated melanoma cell lines were immunoblotted with anti–p-ERK and anti–total ERK. (D) Flow cytometry was performed on melanoma 
cell lines WM2664, SKMEL24, and SKMEL28 (high p-ERK) and melanoma cell lines PMWK, Mel505, and SKMEL187 (low p-ERK). The high 
p-ERK lines express high levels of CD200, while low p-ERK lines express low levels of CD200.
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cell lines with high baseline p-ERK (WM2664 and SKMEL24) after 
as little as 4 hours of treatment with UO126, a pharmacologic 
inhibitor of MEK (Figure 1B). In addition, melanoma cell lines 
WM2664, SKMEL24, and SKMEL28 transduced with a mutant 
BRAF knockdown showed a significant reduction in CD200 mRNA 
expression 4 days after transduction (Supplemental Figure 1A; sup-
plemental material available online with this article; doi:10.1172/
JCI32163DS1). Analysis of a panel of melanoma cell lines with high 
levels of p-ERK showed a greater than 10-fold increase in CD200 
protein expression by flow cytometry when compared with mela-
noma cells with low or absent p-ERK (Figure 1, C and D). These 
data show that CD200 mRNA and protein are dynamic and highly 
expressed ERK targets in melanoma cell lines.
CD200 is highly expressed on melanomas. To support these observa-
tions, the expression of CD200 mRNA and protein was tested in 
groups of resected human tumors. Using a newly developed method 
to perform expression analysis on RNA derived from formalin-fixed, 
paraffin-embedded (FFPE) samples (37), we extracted RNA of suf-
ficient quality for microarray analysis from 20 solid tumors, includ-
ing 6 melanoma metastases, 5 breast cancers, 8 colon cancers, and 1 
lung adenocarcinoma. Through this approach, CD200 mRNA was 
found to be highly expressed in melanomas compared with other 
solid tumors, which have low or absent expression of CD200 mRNA 
(Figure 2A). Furthermore, CD200 mRNA expression strongly corre-
lated in unsupervised hierarchical clustering with other melanoma 
signature transcripts, such as MItF, endothelin receptor type B, and sil-
ver homolog. These results were independently confirmed in publicly 
available microarray data sets analyzing the NCI60 cell lines (38) 
and primary human melanocytic lesions (39) (Supplemental Figure 
2, A and B). In the latter data set from Haqq and colleagues, relative 
CD200 mRNA expression was increased in melanocytic lesions and 
correlated with progression from nevi to melanoma (Supplemen-
tal Figure 2B), in accordance with our demonstration that CD200 
mRNA is regulated by p-ERK. In the NCI60 data set, mRNA levels 
were uniformly higher in melanoma than any other tumor type, 
including the 8 representative leukemia cell lines (Supplemental 
Figure 2A). In aggregate, these data confirm that CD200 mRNA is 
highly and uniformly expressed in the majority of primary mela-
noma but only rarely in other solid tumors.
To confirm these results at the level of protein, we developed 
an immunohistochemical strategy to detect CD200 on FFPE sam-
ples. Upon validation of our immunohistochemical approach on 
known CD200-expressing tissues, placenta and thymus, we turned 
to the analysis of normal skin and 57 resected melanocytic lesions 
including benign and dysplastic nevi, primary melanomas, and 
melanoma metastases (Figure 2B). In accordance with the in vitro 
results (Figure 1A), no CD200 expression of quiescent melanocytes 
residing in normal skin was detected (Figure 2B). In contrast, how-
ever, there was marked expression in the majority of nevi and mela-
nomas (Figure 2B and Table 1). Although CD200 is an ERK target 
in vitro and CD200 mRNA expression correlates with progression, 
CD200 expression as measured by immunohistochemistry (IHC) 
did not correlate with p-ERK staining in melanocytic lesions by 
IHC. In particular, CD200 expression was found throughout the 
entire spectrum of melanocytic neoplasms (Table 1), including 
nevi, whereas p-ERK expression was more frequent in later-stage 
lesions (data not shown). Several possible explanations could rec-
oncile these findings: IHC analysis of p-ERK and CD200 is at best 
semiquantitative and not as reliable as RNA analysis; factors in 
addition to p-ERK likely regulate CD200 expression in nevi (see 
Discussion); or the increased proliferative rates of melanomas 
compared to nevi may dilute the protein expression of this stable 
cell-surface molecule (see below). These concerns notwithstand-
ing, the IHC analyses demonstrate increased expression of CD200 
protein in the majority of human melanocytic neoplasms.
CD200 is required for inhibition of t cell activation. In order to deter-
mine the functional importance of CD200 expression on mela-
noma cell lines, we sought to evaluate the generation of proinflam-
Figure 2
CD200 is expressed on mela-
noma. (A) Dendogram of select 
melanoma-associated tran-
scripts. CD200 expression cor-
relates with other well-estab-
lished melanoma transcripts 
(MITF, DCT, SILV, EDNRB). 
CD200 expression is low or 
absent in colon and most breast 
cancers. SKMEL24 human 
melanoma cell line was used as 
control. (B) IHC for CD200 was 
performed on a series of nor-
mal skin, nevi, and melanomas 
(primary and metastatic). Nor-
mal skin and melanocytes do 
not show CD200 expression, 
while the majority of nevi and 
melanomas strongly express 
CD200. Placenta is shown as a 
positive control; original magni-
fication, ×200.
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matory cytokines induced during a mixed lymphocyte response 
in the presence of melanoma cells with and without physiologi-
cal levels of cell-surface CD200. Although CD200 mRNA rapidly 
plummeted with UO126 treatment (Figure 1B), no change was 
seen in the expression of CD200 on the cell surface even after 48 
hours of UO126 treatment (data not shown), suggesting that the 
cell-surface fraction is highly stable. More prolonged treatment of 
cell lines with U0126 was not possible because of toxicity. In order 
to modulate CD200 expression in melanoma cells, we generated 
a short hairpin RNA (shRNA) construct specifically targeting the 
human CD200 ligand (Supplemental Figure 2A). shRNA oligonu-
cleotides were cloned into a lentiviral transduction vector that also 
harbors EGFP driven by the CMV promoter. Therefore, melanoma 
cells transduced with the CD200 shRNA knockdown construct 
express GFP (Figure 3A). Maximal knockdown of human CD200 
(>6.5 fold by flow cytometry; Supplemental Figure 3B) required 
6 or more passages after transduction (more than 15 days after 
transduction; Figure 3B), suggesting that the membrane-associ-
ated fraction is stable and predominantly decreased on the cell 
surface by dilution with proliferation. CD200 knockdown did not 
alter the in vitro growth or survival of melanoma cell lines. After 
transduction and serial passage, transduced cells were flow sorted 
by GFP to produce cell lines that differed only in their expression 
of CD200 (Figure 3C and Supplemental Figure 3B). In order to 
control for potential effects of RNA interference, melanoma cell 
lines were also transduced with a nonspecific shRNA, which did 
not alter the levels of CD200 expression (Figure 3C).
To investigate the functional importance with regard to the 
immune response of CD200 expression on melanoma cell lines, 
cytokine production during an MLR was evaluated with the addi-
tion of irradiated melanoma cell lines with varying CD200 expres-
sion levels. When human melanoma cell lines WM2664, SKMEL24, 
and SKMEL28, which harbor high p-ERK and CD200 expression, 
were added in an MLR, an inhibitory effect on T cell activation by 
DCs was noted, as evidenced by a significant decrease in IL-2 and 
IFN-γ levels (Figure 4A and Supplemental Figure 4A). In contrast, 
IL-2 and to a lesser extent IFN-γ production was augmented when 
MLRs were performed in the presence of human melanoma cell 
lines PMWK, Mel505, and SKMEL187, which harbor low p-ERK and 
CD200 expression (Figure 1C and Supplemental Figure 4A).
As expression of many factors besides CD200 differed among these 
cell lines, we conducted MLRs with high-CD200-expressing mela-
noma cell lines WM2664, SKMEL24, and SKMEL28 in which the 
expression of CD200 was decreased by shRNA knockdown (WMKD, 
SK24KD, SK28KD, respectively). Inhibition of CD200 expression 
significantly impaired the ability of these cell lines to inhibit T cell 
proliferation when compared with the parental cell lines. In the 
presence of human melanoma cells transduced with CD200-knock-
down shRNA, DC-activated lymphocytes produced increased levels 
of IL-2 and IFN-γ at 72 hours when compared with the parental cell 
lines or cells transduced with nonspecific shRNA (WMNS, SK24NS, 
SK28NS; Figure 4B and Supplemental Figure 4B). A comparable 
inhibition of T cell rosetting was associated with decreased CD200 
expression across the panel of cell lines and with CD200 knockdown 
(Figure 4, C and D, and Supplemental Figure 5, A and B) in the MLRs. 
Therefore, physiological expression of CD200 on the cell surface of 
melanoma cell lines attenuates the ability of DCs to activate T cells.
Discussion
Using multiple melanoma cell lines, we have shown that expression 
of CD200 mRNA and protein is regulated by ERK activation, a sig-
naling event required in the majority of melanomas for progression 
and maintenance. Through an analysis of CD200 mRNA expression 
in FFPE tumors, coupled with comparison of 2 independent pub-
licly available melanoma microarray data sets, we have shown that 
expression of CD200 mRNA correlates with disease progression and 
appears more abundant in melanoma than any other common solid 
tumor or acute leukemia. Finally, we have shown that the endog-
enous CD200 expression on melanoma cell lines represses the abil-
ity of DCs to activate primary T cells in MLRs and that this effect 
is largely abolished by shRNA-mediated knockdown of CD200 in 
these lines. Therefore, the induction of CD200 by ERK activation 
appears to decrease tumor immunogenicity in melanoma.
Recent studies relying, like the present work, on unbiased, 
genome-wide analyses have suggested that CD200 expression 
may play a role in the pathogenesis of B cell lineage malignancies 
and acute leukemia. Moreaux et al. showed that increased CD200 
mRNA expression by microarray correlated with reduced event-
free survival (22 months vs. 14 months) in patients with myeloma 
(40). The effect of CD200 on prognosis was independent of known 
adverse prognostic factors in myeloma, suggesting CD200 expres-
sion per se was pathogenic. A similar result was seen by Tonks 
et al. in acute myeloid leukemia (41). McWhirter et al. showed 
increased CD200 expression in chronic lymphocytic leukemia 
(CLL) samples relative to normal B cells. In accordance with our 
findings, the authors also showed that CD200 expression is associ-
ated with decreased CLL cell immunogenicity in an MLR (42). This 
effect could be partially blocked by incubation of the CLL cells 
with anti-CD200 antibodies, concordant with results seen using 
CD200 shRNA. In aggregate, these data suggest a pathogenic role 
of CD200 expression in certain hematologic malignancies.
We have extended these results to melanoma, an important 
human solid tumor for which ample evidence suggests there is a 
clinically beneficial antitumor immune response in some patients. 
In the NCI60 cell line data set (Supplemental Figure 2A) as well as 
FFPE samples (Figure 2A), CD200 mRNA expression was higher and 
more ubiquitous in melanoma compared with other solid tumors, 
although it is likely that other tumors in these data sets also harbor 
ERK activation. Therefore, although CD200 mRNA is induced by 
p-ERK in melanoma cell lines, this p-ERK responsiveness appears 
to be relatively restricted to melanocytic cell types. This finding 
would be consistent with the view that melanocyte-specific factors 
regulate CD200 mRNA expression in combination with p-ERK. It is 
worth noting, however, that increased CD200 expression was also 
detected in a small subset of samples of other solid tumors, such as 
breast, ovarian, and lung cancers (see Figure 2A and Supplemental 
Figure 2A). Therefore, CD200 expression may play a role in the dis-
ease pathogenesis of subsets of other solid tumors as well.
We believe these findings have important and direct clinical rel-
evance to the treatment of melanoma. For example, while there is 
Table 1
CD200 expression in melanocytic lesions by IHC
Lesion	 CD200	staining	(medium	to	high)
Nevi 27 of 34 (79%)
Melanoma 11 of 23 (48%)
Total 38 of 57 (67%)
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some enthusiasm in the field of melanoma therapy to combine 
novel RAF and MEK inhibitors, which inhibit proliferation, with 
classical chemotherapeutic agents, which target cycling cells, our 
data suggest that the combination of such targeted kinase inhibi-
tors with immunomodulatory agents such as IL-2 or IFN is at least 
as rational a strategy. Moreover, as at least one CD200 blocking anti-
body is in preclinical development for cancer therapy (Alexion Phar-
maceuticals), this work has important implications for the develop-
ment of anticancer therapies to target directly the CD200-CD200R 
interaction. While blocking antibodies against CTLA4 have shown 
promising single-agent activity in melanoma, it is important to note 
that response to anti-CTLA4 seems to correlate with the develop-
ment of significant immune enterocolitis (15). Patients who had 
the most severe autoimmune stigmata appeared to derive the great-
est benefit from CTLA4 blockade. In this regard, it is encouraging 
to note that the CD200-knockout mice demonstrate a much less 
severe autoimmune phenotype than CTLA4-deficient mice (25, 43, 
44), suggesting that blockade of CD200 will be better tolerated than 
that of CTLA4. Last, we believe these data suggest that melanoma is 
perhaps the best candidate disease for the testing and development 
of anti-CD200 approaches. In particular, patients with melanoma 
who are candidates for phase I therapies are not rare and tend to be 
younger, less heavily pretreated, and of better performance status 
than patients with refractory hematologic malignancies, who are 
uncommon and generally heavily pretreated prior to consideration 
for a phase I trial. Therefore, we believe this identification of mela-
Figure 3
shRNA-mediated knockdown of CD200 expression. (A) WM2664 human melanoma cells were transduced with a GFP-expressing human 
CD200 shRNA construct and stained with an anti-human CD200 antibody (red). Untransduced WM2664 cells expressed CD200 (red). Trans-
duced WM2664 cells were negative for CD200 expression. Nuclei of cells are stained with DAPI (blue). Original magnification, ×40. (B) CD200 
expression at different passages in culture after transduction was analyzed by flow cytometry. Efficient knockdown of the CD200 protein was 
observed after 6 passages (>15 days) in culture. (C) WM2664 human melanoma cells were FACS sorted for GFP expression and then analyzed 
by immunofluorescence for CD200 expression. WM2664 cells transduced with a CD200 shRNA were negative for CD200 expression. WM2664 
cells transduced with a nonspecific shRNA showed intense staining for CD200 (red). Original magnification, ×10.
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noma as a rational target disease will facilitate the development of 
CD200-CD200R anticancer therapies.
Methods
Cell lines. Human melanoma cell lines WM2664 and PMWK were obtained 
from J. Arbiser (Emory University, Atlanta, Georgia, USA); Mel505 was 
obtained from J. Hansson (Karolinska Institute, Stockholm, Sweden); 
SKMEL187 was obtained from A. Houghton (Memorial Sloan-Kettering 
Cancer Center, New York, New York, USA); and SKMEL24, SKMEL28, and 
293FT were obtained from ATCC. Cells were cultured in either DMEM 
with the addition of 10% FBS and penicillin/streptomycin (WM2664, 
293FT, PMWK, SKMEL187), MEM-α with the addition of 10% nones-
sential amino acids and 10% FBS and penicillin/streptomycin (SKMEL24, 
SKMEL28), or RPMI with addition of 10% FBS and penicillin/streptomy-
cin (Mel505) (Gibco; Invitrogen). Human melanoma cell lines, WM2664, 
SKMEL24, SKMEL28, SKMEL187, and Mel505, were derived from verti-
cal growth phase melanomas, and human melanoma cell line PMWK was 
derived from a radial growth phase melanoma. Cells were incubated at 
37°C, 5% CO2, and medium was changed every other day. Subconfluent 
cells were trypsinized and replated at the appropriate densities. Human DCs 
were differentiated using CD34+ selection (Miltenyi Biotec) following a 15-l 
apheresis collection of peripheral blood (Cobe-Spectra; GambroBCT). DCs 
were expanded first in the presence of GM-CSF (Immunex), FLT3-ligand, 
IL-4, stem cell factor, and TNF-α (Peprotech) using AIM-V media (Gibco; 
Invitrogen) with 10% human AB serum (Gemini Bio-Products). Microarray 
analysis, TaqMan (Applied Biosciences) analysis, ERK and BRAF Western 
blot analysis, and ERK inhibition with UO126 of melanoma cell lines were 
performed as described previously (2, 45).
Figure 4
CD200 is required for T cell repression. (A) IL-2 production by T lymphocytes during MLRs with the addition of human melanoma cell lines 
with varying levels of CD200 expression. WM2664, SKMEL24, and SKMEL28 express high levels of CD200; PMWK, Mel505, and SKMEL187 
express low levels of CD200. IL-2 production, as a marker of T cell activation, was determined by ELISA after 72 hours of incubation. Indicated 
statistical comparisons are between the indicated cell line versus T cells plus DCs only (**P < 0.005; ***P < 0.0001). Error bars are ± SEM. (B) 
MLRs in the presence of WM2664, SKMEL24, and SKMEL28 transduced with nonspecific hairpin (WMNS, SK24NS, SK28NS) and WM2664, 
SKMEL24, and SKMEL28 transduced with CD200 knockdown (WMKD, SK24KD, SK28KD). DCs and T cells were mixed with the indicated 
human melanoma cell lines with or without CD200 shRNA knockdown. IL-2 production was significantly higher in CD200-knockdown melanoma 
cell lines (WMKD, SK24KD, SK28KD) when compared with the parental melanoma cell lines transduced with a nonspecific shRNA (WMNS, 
SK24NS, and SK28NS). Error bars are ± SEM. (C) Quantification of T cell rosettes. WMKD and SK24KD show a significant increase in the 
formation of T cell rosettes when compared with their parental cell lines transduced with a nonspecific shRNA in MLRs. A mix of T cells and DCs 
was used as a positive control (far-left bar). Error bars are ± SEM. (D) WMKD and SK24KD show a significant increase in the formation of T cell 
rosettes when compared with their parental cell lines transduced with a nonspecific shRNA in MLRs. A mix of T cells and DCs was used as a 
positive control (far-left panel). Original magnification, ×100.
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MLRs. MLRs were set up in 12-well plates using 1 × 105 DCs and 2 × 106 T 
cells. T cells were enriched by incubating the cells for 2 hours in tissue cul-
ture flasks and taking the nonadherent cell fraction. Irradiated melanoma 
cell lines (250,000 per reaction) were added to the MLRs at the start of the 
experiment, and supernatants were collected after 72 hours and analyzed 
for the presence of IL-2 and IFN-γ.
IL-2 and IFN-γ ELISA. Conditioned medium was obtained from mixed 
lymphocytic reactions and assayed for the presence of IL-2 and IFN-γ by 
ELISA following the manufacturer’s instructions (Quantikine Kit; R&D 
Systems). OD measurements were performed using a Kinetic Microplate 
Reader (Molecular Devices). T cells plus DCs in the absence of melanoma 
cells and melanoma cells alone (data not shown) were used as controls.
DNA constructs, viral production, and infection of target cells. shRNA cod-
ing oligonucleotides were designed and verified to be specific for human 
CD200 according to a BLAST search (http://www.ncbi.nlm.nih.gov/blast/) 
against human genome. The human CD200 shRNA targeting sequence was 
5′-TGGTAATTCTTCTCGTCCTGTTCAAGAGATAGGACGAGAAGAAT-
TACCTTTTTTTTC-3′. The insert was cloned between the XhoI and HpaI 
sites of the pLentiLox 3.7 vector. A nonspecific shRNA construct was used 
as control. The production of lentiviruses in 293FT cells and infection of 
target cells were as described previously (46). WM2664 and SKMEL24 cells 
were infected with the viral supernatant, CD200 expression levels were 
analyzed, and positive cells were sorted by flow cytometry. BRAF mutant 
shRNA (pSuper) plasmid or scrambled nonspecific shRNA (pSuper) plas-
mid, as previously described (45), was added to 293FT cells for the produc-
tion of retrovirus. WM2664, SKMEL24, and SKMEL28 cells were infected 
with viral supernatant for 24 hours; cells were selected in media containing 
5 μg/ml puromycin for 4–5 days; and CD200 expression levels were ana-
lyzed by TaqMan quantitative RT-PCR.
Flow cytometry. Exponentially growing cells were detached using 0.5 mM 
EDTA for 3–5 minutes at 37°C and stained with FITC-conjugated anti-
bodies against the CD200 surface antigen (MCA1958FA; Serotec) analyzed 
using a FACScan analytical flow cytometer (BD Biosciences — Immuno-
cytometry Systems). Appropriately gated cells were analyzed (10,000 cells 
counted per staining) and compared with unstained or isotype controls.
Indirect immunofluorescence analysis and image acquisition. Cells were plated 
on glass coverslips and fixed with 4% PFA. After washing and blocking 
with PBS plus 10% FBS, cells were stained with mouse anti-human CD200 
antibody (1:100 dilution; R&D Systems), followed by incubation with 
594AlexaFluor-conjugated goat anti-mouse secondary antibody (Neomark-
ers). Cell-containing coverslips were mounted onto glass slides, and nuclei 
were counterstained using DAPI-Vectashield (Vector Laboratories). Cells 
were visualized and photographed using a fluorescence microscope (model 
IX-81; Olympus) equipped with an X60 1.45 NA objective, a CCD camera 
(model C4742-80-12AG; Hamamatsu), and controlled by AQM Advanced 
6 software (Kinetic Imaging Ltd.).
RNA analysis and IHC on nevi and melanomas. RNA from FFPE tumors 
samples of 2–8 years of age was prepared using a commercially available 
FFPE extraction kit (Arcturus) and amplified and labeled as described pre-
viously (37). Amplified RNA from tumors was hybridized to the Agilent 
22K 3′-biased arrays and analyzed by unsupervised hierarchical clustering. 
An excerpted cluster of this analysis is shown in Figure 2A. See ref. 37 for 
details and primary data; all primary microarray data can be downloaded 
from the UNC microarray database (see the “published data” link; https://
genome.unc.edu/).
The study was approved by the Institutional Review Board of the University 
of North Carolina. The tissues used in this study were selected at random 
from a series of cases treated at UNC Hospitals after 2000. All cases, including 
23 melanomas and 34 benign nevi, underwent standardized histopathology 
review of H&E-stained sections of the specimens for confirmation of diagno-
sis and evaluation of lesional characteristics. Five-micrometer sections were 
deparaffinized and stained using a commercially available CD200 antibody 
(AF2724; R&D) at a dilution of 1:50 with immunodetection by HRP after 
Tris-EDTA antigen retrieval. Staining was validated on control tissues (pla-
centa and thymus) consistent with the known pattern of expression of CD200 
in these organs. All tissues were scored for staining intensity for localization, 
percentage of cells, and intensity of staining. For the majority of nevi and 
melanomas, more than 50% of the cells stained with the CD200 antibody. The 
CD200 localization was cytoplasmic or both cytoplasmic and membranous. 
The intensity was scored as none, low, medium, or high and dichotomized as 
none-to-low versus medium-to-high for the purposes of this article.
Statistics. For comparisons shown in Figures 1 and 4, a 2-tailed Student’s t 
test was used. A P value of less than 0.05 was considered significant. Analyses 
were performed using GraphPad Prism Software version 3.0.
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